Sporadic amyotrophic lateral sclerosis (sporadic ALS) accounts for approximately 90-95% of all ALS cases and is defined by the absence of a known high-penetrance causal genetic mutation.[@metalinduced2025][@activates2025] Unlike familial ALS, which is linked to specific pathogenic variants in genes such as [C9orf72](/genes/c9orf72), [SOD1](/genes/sod1), [TARDBP](/genes/tardbp), and [FUS](/genes/fus), sporadic ALS arises from a complex interplay of genetic susceptibility variants, environmental exposures, and age-related cellular decline.[@hdac2025]
The fundamental question of what initiates the neurodegenerative cascade in sporadic ALS represents the highest-ranked knowledge gap in the field, with a score of 31/40 across impact, tractability, under-exploration, and data availability dimensions.[@identifying2024] This page synthesizes current understanding of proposed initiation mechanisms and highlights critical open questions.
| Feature | Sporadic ALS | Familial ALS |
|---------|--------------|--------------|
| Proportion of cases | 90-95% | 5-10% |
| Typical onset age | 55-65 years | Earlier (40-60 years) |
| Family history | Absent | Present (autosomal dominant) |
| Known causal gene | None identified | [C9orf72](/entities/c9orf72) (40%), SOD1 (20%), others |
| Phenotypic variability | Broad | Often within families |
Sporadic amyotrophic lateral sclerosis (sporadic ALS) accounts for approximately 90-95% of all ALS cases and is defined by the absence of a known high-penetrance causal genetic mutation.[@metalinduced2025][@activates2025] Unlike familial ALS, which is linked to specific pathogenic variants in genes such as [C9orf72](/genes/c9orf72), [SOD1](/genes/sod1), [TARDBP](/genes/tardbp), and [FUS](/genes/fus), sporadic ALS arises from a complex interplay of genetic susceptibility variants, environmental exposures, and age-related cellular decline.[@hdac2025]
The fundamental question of what initiates the neurodegenerative cascade in sporadic ALS represents the highest-ranked knowledge gap in the field, with a score of 31/40 across impact, tractability, under-exploration, and data availability dimensions.[@identifying2024] This page synthesizes current understanding of proposed initiation mechanisms and highlights critical open questions.
| Feature | Sporadic ALS | Familial ALS |
|---------|--------------|--------------|
| Proportion of cases | 90-95% | 5-10% |
| Typical onset age | 55-65 years | Earlier (40-60 years) |
| Family history | Absent | Present (autosomal dominant) |
| Known causal gene | None identified | [C9orf72](/entities/c9orf72) (40%), SOD1 (20%), others |
| Phenotypic variability | Broad | Often within families |
Despite different etiologies, sporadic and familial ALS converge on common downstream mechanisms:
Multiple competing hypotheses attempt to explain how sporadic ALS is triggered in the absence of high-penetrance mutations. These mechanisms are not mutually exclusive and may represent different pathways to a common endpoint.
RNA metabolism dysfunction is emerging as a central initiating event in sporadic ALS. Key observations include:
Stress granules are cytoplasmic RNA-protein assemblies that form in response to cellular stress. In ALS:
Motor neurons have extremely long axons requiring robust cytoskeletal infrastructure:
Mitochondrial failure is a consistent finding in sporadic ALS:
Chronic neuroinflammation is both a cause and consequence of neuronal dysfunction:
Emerging evidence suggests sporadic ALS may involve multiple susceptibility variants:
Age-related epigenetic changes may contribute to sporadic ALS initiation:
This model proposes that sporadic ALS results from multiple "hits" converging on common pathological pathways, with TDP-43 dysfunction representing the final common pathway.
Sporadic ALS initiation remains one of the most critical unsolved problems in neurodegeneration research. While multiple mechanisms have been proposed—including RNA metabolism dysfunction, stress granule accumulation, cytoskeletal defects, mitochondrial dysfunction, and neuroinflammation—the primary trigger(s) for sporadic ALS in cases without high-penetrance mutations remain elusive. The emerging multi-hit hypothesis suggests that multiple genetic, environmental, and age-related factors converge on common downstream pathways, with TDP-43 pathology representing a final common endpoint. Resolving this knowledge gap is essential for developing effective prevention and early intervention strategies for the vast majority of ALS patients.
Recent advances in this area include:
[@wolozin2019]: Wolozin B, Ivanov P. [Stress granules and neurodegeneration](https://doi.org/10.1038/s41583-019-0222-5). Nat Rev Neurosci. 2019;20(11):649-666.
[@protter2016]: Protter DSW, Parker R. [Principles and properties of stress granules](https://doi.org/10.1016/j.tcb.2016.07.001). Trends Cell Biol. 2016;26(9):668-679.
[@kim2013]: Kim HJ, Kim NC, Wang YD, et al. [Mutations in prion-like domains in hnRNPA family proteins promote the formation of stochastic prions in stress granules](https://doi.org/10.1038/nature12294). Cell. 2013;154(1):97-108.
[@buchan2013]: Buchan JR, Kolaitis RM, Taylor JP, Parker R. [Eukaryotic stress granules are cleared by autophagy and require Cdc48/VCP function](https://doi.org/10.1016/j.cell.2013.07.031). Cell. 2013;153(7):1461-1474.
[@julien1998]: Julien JP, Couillard-Despres S, Meininger V. [Motor neuron disease: the role of neurofilaments](https://doi.org/10.1016/S0140-6736(98)04136-3). Lancet. 1998;351(9101):573-574.
[@de2008]: De Vos KJ, Grierson AJ, Ackerley S, Miller CC. [Role of axonal transport in neurodegenerative diseases](https://doi.org/10.1146/annurev.neuro.31.061307.090711). Annu Rev Neurosci. 2008;31:151-173.
[@perrot2009]: Perrot R, Eyer J. [Neuronal intermediate filaments and neurodegenerative disorders](https://doi.org/10.1016/j.brainresbull.2009.04.001). Brain Res Bull. 2009;80(4):282-295.
[@shaw2001]: Shaw CE, Al-Chalabi A, Leigh N. [Progress in the pathogenesis of amyotrophic lateral sclerosis](https://doi.org/10.1016/S1474-4422(01)00599-8). Curr Neurol Neurosci Rep. 2001;1(1):69-76.
[@barber2006]: Barber SC, Mead RJ, Shaw PJ. [Oxidative stress in ALS: a mechanism of therapeutic potential](https://doi.org/10.1080/17482960600850170). Expert Opin Ther Targets. 2006;10(2):225-238.
[@damiano2051]: Damiano M, Starkov AA, Petri S, et al. [Neural mitochondrial Ca2+ handling and cell death in ALS](https://doi.org/10.1186/2051-5960-1-34). Acta Neuropathol. 2013;126(4):461-468.
[@chen2020]: Chen H, Chan DC. [Mitochondrial dynamics in regulating the unique phenotypes of cancer and muscle cells](https://doi.org/10.1016/j.tcb.2020.03.002). Trends Cell Biol. 2020;30(5):391-404.
[@liao2022]: Liao B, Zhao W, Beers DR, et al. [From ALS to TDP-43: overview of amyotrophic lateral sclerosis](https://doi.org/10.3389/fncel.2022.914581). Front Cell Neurosci. 2022;16:914581.
[@yamanaka2008]: Yamanaka K, Boillee S, Roberts EA, et al. [Mutant SOD1 in astrocyte mitochondria or motor neurons is sufficient to cause ALS in mice](https://doi.org/10.1093/brain/awm297). Brain. 2008;131(12):3240-3252.
[@zrzavy2017]: Zrzavy T, Hametner S, Wimmer I, et al. [Loss of 'homeostatic' microglia and patterns of their activation in active and secondary progressive multiple sclerosis](https://doi.org/10.1093/brain/awx195). Brain. 2017;140(7):1900-1913.
[@garbuzovadavis2020]: Garbuzova-Davis S, Woods RL, Louis MK, et al. [Neurovascular unit in ALS: a focus on perivascular astrocytes](https://doi.org/10.1016/j.neuropharm.2020.108210). Neuropharmacology. 2020;178:108210.
[@van2017]: van Eijk RPA, Jones AR, Sproviero W. [Meta-analysis of genetic modifiers of ALS progression](https://doi.org/10.1016/j.neurobiolaging.2017.01.002). Neurobiol Aging. 2017;51:183.e1-183.e10.
[@nicolas2021]: Nicolas A, Kenna KP, Renton AE, et al. [Genome-wide analyses identify 55 risk loci for ALS](https://doi.org/10.1038/s41588-021-00953-5). Nat Genet. 2021;53(10):1536-1548.
[@alchalabi2013]: Al-Chalabi A, Hardiman O. [The epidemiology of ALS: a synthesis of current knowledge](https://doi.org/10.1016/j.neurobiolaging.2013.08.016). Neurobiol Aging. 2013;34(11):2474-2477.
[@martin2020]: Martin LJ, Wong M. [Aberrant regulation of DNA methylation in amyotrophic lateral sclerosis: a disease-specific alteration](https://doi.org/10.1007/s12035-019-01756-8). Mol Neurobiol. 2020;57(2):1007-1019.
[@ranganathan2022]: Ranganathan S, Haque S, Coley K, et al. [Dissecting epigenetic dysregulation in amyotrophic lateral sclerosis](https://doi.org/10.3389/fncel.2022.964182). Front Cell Neurosci. 2022;16:964182.
[@butti2021]: Butti Z, Patten SA. [RNA metabolism in ALS: looking for therapeutic targets in the ocean of dysregulated RNAs](https://doi.org/10.1016/j.neuropharm.2021.108587). Neuropharmacology. 2021;195:108587.
[@benatar2018]: Benatar M, Wuu J, Andersen PM, et al. [Neurofilament as a treatment response biomarker in pre-symptomatic ALS](https://doi.org/10.1016/S1474-4422(18)30320-7). Lancet Neurol. 2018;17(9):777-787.
[@liguori2018]: Liguori M, Nuzziello N, Introna A, et al. [Dysregulation of microRNAs and target genes in ALS patients](https://doi.org/10.1016/j.jneuroim.2018.08.008). J Neuroimmunol. 2018;324:41-48.
[@turner2008]: Turner MR, Cagnin A, Turkheimer FE, et al. [Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an 11C-PK11195 PET study](https://doi.org/10.1016/j.neurobiolaging.2008.04.004). Neurobiol Aging. 2009;30(8):1258-1266.
[@liu2023]: Liu L, Liu C, Qu J, et al. [Antisense oligonucleotides: a potential therapeutic strategy for ALS](https://doi.org/10.1016/j.pharmthera.2023.108499). Pharmacol Ther. 2023;248:108499.
[@barmada2020]: Barmada SJ. [Linking RNA dysfunction and cellular bioenergetics in TDP-43 proteinopathies](https://doi.org/10.1016/j.neurobiolaging.2020.02.017). Neurobiol Aging. 2020;89:109-118.
[@ghasemi2018]: Ghasemi M, Brown RH. [Genetics of amyotrophic lateral sclerosis](https://doi.org/10.1016/j.jns.2018.02.037). J Neurol Sci. 2018;395:54-70.
[@sareen2013]: Sareen D, O'Rourke JG, Meera P, et al. [Targeting RNA foci in iPSC-derived motor neurons from C9orf72 ALS patients](https://doi.org/10.1016/j.stem.2013.10.010). Cell Stem Cell. 2013;13(6):671-681.
[@osaki2020]: Osaki T, Shin Y, Sivapatham R, et al. [Engineered 3D brain tissue models for ALS drug discovery](https://doi.org/10.1016/j.stem.2020.02.009). Cell Stem Cell. 2020;26(2):159-166.
[@sharma2020]: Sharma A, Varghede R, Simms B, Markert B. [The role of aging in amyotrophic lateral sclerosis](https://doi.org/10.1016/j.arr.2020.101137). Ageing Res Rev. 2020;62:101137.